FI930846A0 - Homokonjugerade immunoglobuliner - Google Patents
Homokonjugerade immunoglobulinerInfo
- Publication number
- FI930846A0 FI930846A0 FI930846A FI930846A FI930846A0 FI 930846 A0 FI930846 A0 FI 930846A0 FI 930846 A FI930846 A FI 930846A FI 930846 A FI930846 A FI 930846A FI 930846 A0 FI930846 A0 FI 930846A0
- Authority
- FI
- Finland
- Prior art keywords
- immunoglobuliner
- homoconjugerade
- homoconjugerade immunoglobuliner
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57572590A | 1990-08-31 | 1990-08-31 | |
| US74866291A | 1991-08-26 | 1991-08-26 | |
| PCT/US1991/006195 WO1992004053A1 (en) | 1990-08-31 | 1991-08-29 | Homoconjugated immunoglobulins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI930846A0 true FI930846A0 (fi) | 1993-02-25 |
| FI930846A FI930846A (fi) | 1993-04-05 |
Family
ID=27076774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI930846A FI930846A (fi) | 1990-08-31 | 1993-02-25 | Homokonjugerade immunoglobuliner |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0547137A4 (fi) |
| JP (1) | JPH06500780A (fi) |
| KR (1) | KR930702029A (fi) |
| AU (1) | AU8506991A (fi) |
| CA (1) | CA2090317A1 (fi) |
| FI (1) | FI930846A (fi) |
| IE (1) | IE913071A1 (fi) |
| IL (1) | IL99363A0 (fi) |
| NZ (1) | NZ239617A (fi) |
| PT (1) | PT98840A (fi) |
| WO (1) | WO1992004053A1 (fi) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2281300A (en) * | 1993-08-26 | 1995-03-01 | Merck & Co Inc | Anti-HIV antibody oligomer |
| US6368596B1 (en) | 1997-07-08 | 2002-04-09 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CN102746404B (zh) | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1931709B1 (en) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| CA2625998C (en) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| AU2007285976B2 (en) | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
| CA2660795C (en) | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| PL2235059T3 (pl) | 2007-12-26 | 2015-08-31 | Xencor Inc | Warianty FC o zmodyfikowanym wiązaniu do FCRN |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| WO2010112194A1 (en) | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
| RU2598248C2 (ru) | 2009-04-02 | 2016-09-20 | Роше Гликарт Аг | Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab |
| PE20120550A1 (es) | 2009-04-07 | 2012-05-21 | Roche Glycart Ag | ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET |
| CN102361884A (zh) | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-2/抗-c-Met抗体 |
| EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| RU2573915C2 (ru) | 2009-09-16 | 2016-01-27 | Дженентек, Инк. | Содержащие суперспираль и/или привязку белковые комплексы и их применение |
| WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
| MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
| BR112014024903A2 (pt) | 2012-04-05 | 2017-07-11 | Hoffmann La Roche | anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos |
| MX354862B (es) | 2012-06-27 | 2018-03-23 | Hoffmann La Roche | Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes. |
| MX2014014804A (es) | 2012-06-27 | 2015-02-12 | Hoffmann La Roche | Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo. |
| BR112014030843A2 (pt) | 2012-07-04 | 2019-10-15 | Hoffmann La Roche | anticorpo anti-teofilina, formulação farmacêutica e uso do anticorpo |
| SI2869848T1 (sl) | 2012-07-04 | 2017-01-31 | F. Hoffmann-La Roche Ag | Kovalentno vezani konjugati antigen-protitelo |
| EP2870180B1 (en) | 2012-07-04 | 2024-08-28 | F. Hoffmann-La Roche AG | Anti-biotin antibodies and methods of use |
| CN104341504B (zh) | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
| JP6608827B2 (ja) | 2013-12-20 | 2019-11-20 | エフ．ホフマン−ラ ロシュ アーゲー | ヒト化抗タウ（ｐＳ４２２）抗体及び使用方法 |
| CN105873615B (zh) | 2014-01-03 | 2020-12-25 | 豪夫迈·罗氏有限公司 | 共价连接的helicar-抗helicar抗体缀合物及其用途 |
| PL3089996T3 (pl) | 2014-01-03 | 2021-12-13 | F. Hoffmann-La Roche Ag | Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg |
| RU2682754C2 (ru) | 2014-01-03 | 2019-03-21 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| EP3744732A1 (en) | 2015-06-24 | 2020-12-02 | F. Hoffmann-La Roche AG | Humanized anti-tau(ps422) antibodies and methods of use |
| JP7169985B2 (ja) * | 2017-11-07 | 2022-11-11 | ヒュービットジェノミクス株式会社 | ＩｇＥクラスに特異的な免疫反応の抑制効果を介した乳児期のアレルギー素因獲得を阻止する方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422653D0 (en) * | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
| WO1991006305A1 (en) * | 1989-11-07 | 1991-05-16 | Bristol-Myers Squibb Company | Oligomeric immunoglobulins |
-
1991
- 1991-08-29 WO PCT/US1991/006195 patent/WO1992004053A1/en not_active Application Discontinuation
- 1991-08-29 KR KR1019930700605A patent/KR930702029A/ko not_active Application Discontinuation
- 1991-08-29 CA CA002090317A patent/CA2090317A1/en not_active Abandoned
- 1991-08-29 EP EP19910916502 patent/EP0547137A4/en not_active Ceased
- 1991-08-29 AU AU85069/91A patent/AU8506991A/en not_active Abandoned
- 1991-08-29 JP JP3515144A patent/JPH06500780A/ja active Pending
- 1991-08-30 PT PT98840A patent/PT98840A/pt not_active Application Discontinuation
- 1991-08-30 IE IE307191A patent/IE913071A1/en unknown
- 1991-08-30 NZ NZ239617A patent/NZ239617A/xx unknown
- 1991-09-01 IL IL99363A patent/IL99363A0/xx unknown
-
1993
- 1993-02-25 FI FI930846A patent/FI930846A/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06500780A (ja) | 1994-01-27 |
| EP0547137A1 (en) | 1993-06-23 |
| WO1992004053A1 (en) | 1992-03-19 |
| CA2090317A1 (en) | 1992-03-01 |
| EP0547137A4 (en) | 1993-12-08 |
| NZ239617A (en) | 1993-11-25 |
| FI930846A (fi) | 1993-04-05 |
| PT98840A (pt) | 1992-07-31 |
| IL99363A0 (en) | 1992-08-18 |
| IE913071A1 (en) | 1992-03-11 |
| KR930702029A (ko) | 1993-09-08 |
| AU8506991A (en) | 1992-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI924473A0 (fi) | Haorfoermningsschampo | |
| SE9200690L (sv) | Dekaltryckfoerfarande | |
| ATA150090A (de) | Hoergeraet | |
| NO913680L (no) | Stoevsugerpose | |
| FI930846A0 (fi) | Homokonjugerade immunoglobuliner | |
| FI930295A (fi) | Haorformningsgelkomposition | |
| DK0463302T3 (da) | Klemhane | |
| FI932833A (fi) | Koppling foer flaensroer | |
| FI925980A (fi) | Bisheterocykliska foereningar | |
| FI925180A (fi) | Saetesoeverdrag | |
| ATA210290A (de) | Lotpille | |
| FI925356A0 (fi) | Fastspaenningslock foer rullningshylsor | |
| ATA80690A (de) | Alpinschi | |
| ATA200090A (de) | Pianino | |
| ATA237490A (de) | Rinnenstein | |
| ATA209290A (de) | Diaraehmchen | |
| NO920463D0 (no) | Indol-derivater | |
| KR910014306U (ko) | 소화전 | |
| BR7000375U (pt) | Mosquiteiro baby-ju | |
| BR7000286U (pt) | Barraca-bagageiro | |
| BR7000495U (pt) | Disjuntor salva-vidas | |
| DK296990A (da) | Paskvil | |
| BR7000649U (pt) | Autoar | |
| ATA70290A (de) | Anzeigetafel | |
| ATA25990A (de) | Wandstein |